What are the next steps for the bill, and how likely is it that it will become law? Here’s are four things MCOs should know.
On May 4, the House passed legislation that would replace the Affordable Care Act (ACA) by voting 217 to 213 in support of the revised American Health Care Act (AHCA). No Democrats voted for the bill, and 20 Republications voted against it.
So what are the next steps for the bill, and how likely is it that it will become law? Here’s are four things MCOs should know.
Senate procedural rules favor more debate than House rules, which will stretch out the time it takes for a vote. “The Senate will need time to reach consensus on complex issues,” says Harry Nelson, a healthcare attorney with Nelson Hardiman LLP and author of “From ObamaCare to TrumpCare.” “Republican senators whose states expanded Medicaid are at odds with senators whose states refused expansion funds. Issues like protecting low-income seniors and funding state high-risk pools will also take time to debate.”
Garrett Fenton, JD, member, Miller & Chevalier, a law firm with a specialty in healthcare, points out that the Senate needs to wait until the nonpartisan Congressional Budget Office issues an updated report (or score) on the estimated impact of the AHCA (including the most recently-adopted amendments) on the federal budget and rate of uninsured individuals. The updated score is not expected to be published until May 22 at the earliest.
The narrower Republican majority and the voting power of more moderate Republican senators, including those from states that expanded Medicaid, will likely lead to a more liberal bill that offers more protection of individuals with preexisting conditions and less reduction of Medicaid funding, Nelson says.
Fenton says some Senators have expressed concerns with various AHCA provisions, including waivers that would allow states to redefine the essential health benefits that individual and small group market plans generally must cover (and upon which all plans must not impose annual or lifetime dollar limits), permit insurers to rate individuals based on their health status, and allow insurers to charge older enrollees more than their younger counterparts-by an even greater factor than 5:1 (which the AHCA already purports to increase from the 3:1 maximum factor currently allowed under the ACA).
In addition, some Senate Republicans are concerned about the AHCA's phasing out of the ACA's Medicaid expansion and transition to a "per capita cap" system, defunding of Planned Parenthood, and structuring the new tax credit system for individual market coverage, Fenton says. A 13-member Republican Senate healthcare working group has formed to work out the details of the forthcoming bill.
Fenton also notes that from a procedural standpoint, the legislation may need to be modified in order to comport with the Senate's budget reconciliation rules. “The House is not subject to the same rules, so some of the current AHCA provisions that ultimately helped gain the support of many House Republicans may be at risk of being removed or drastically modified in the Senate,” he says.
Next: Will the Senate pass a revised bill?
3. The Senate might pass a revised bill.
Nelson believes the Senate will likely pass a bill, but it will have substantial differences from the House bill. “Passage is a political necessity because Republicans will have ‘egg on their face’ for not making good on their promise to ‘repeal and replace’ the ACA after seven years, and also because Republicans share the overriding goals of delegating power to the states to set insurance rules and pass a tax reform bill later in the year,” he says.
Fenton believes that the Senate could pass its own version of legislation. “But will House Republicans maintain their already razor-thin support for the AHCA once Senate changes are made?” he asks.
4. If the Senate passes the bill and President Trump signs it into law, some provisions could be effective right away.
Fenton says that some provisions of the House-passed AHCA would take effect immediately, and even retroactively in some cases (e.g., individual and employer mandates would be repealed as of January 1, 2016, and the annual fee on health insurers would be repealed effective January 1, 2017). Some provisions repealing certain ACA taxes and expanding health savings accounts would become law as soon as 2018, while other AHCA repeals and modifications (and potential state waivers) of certain market reforms would take effect beginning in 2020, and still other provisions would be delayed further (e.g., the Cadillac tax would not take effect until 2026, rather than 2020 as under current law).
Karen Appold is a medical writer in Lehigh Valley, Pennsylvania.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Inflation Reduction Act: Reforms to Patient Cost-Sharing
September 18th 2023Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.
Read More
Spending climbed by 2.7% in 2021. In 2020, it soared by 10.3%, fueled by federal government spending in response to the pandemic. The blizzard of calculations of 2021 healthcare spending by CMS’ actuaries also provides further evidence that utilization of healthcare services bounced back in 2021.
Read More
Talking PIE, the Act, Before Thanksgiving
November 23rd 2022AMCP CEO Susan A. Cantrell spoke with Managed Healthcare Executive® about Preapproval Information Exchange (PIE) Act of 2022, which would allow drug manufacturers to share information about a drug with payers before the drug is approved. Cantrell says passage of the PIE Act would speed up patient access to new medications.
Read More
Inflation Reduction Act and the Impact on Pharmaceutical Pricing and Investment Decisions
November 21st 2022The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.
Read More